NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

LLY

Lilly(Eli) & Co

Jul 01 • 04:00PM ET

775.90

Dollar change -3.63
Percentage change -0.47	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: NVO JNJ ABBV MRK AZN AMGN PFE SNY BMY GSK

| Held by: VTI VOO SPY IVV VUG XLV VIG IWF QUAL VHT

Scroll to Statements

Index	S&P 500	P/E	64.28	EPS (ttm)	12.07	Insider Own	10.35%	Shs Outstand	948.10M	Perf Week	-0.28%
Market Cap	735.35B	Forward P/E	26.06	EPS next Y	29.77	Insider Trans	-0.89%	Shs Float	849.66M	Perf Month	5.18%
Enterprise Value	770.73B	PEG	1.54	EPS next Q	5.57	Inst Own	73.63%	Short Float	0.94%	Perf Quarter	-6.06%
Income	11.11B	P/S	15.01	EPS this Y	67.36%	Inst Trans	0.77%	Short Ratio	1.95	Perf Half Y	-2.30%
Sales	49.00B	P/B	46.66	EPS next Y	36.96%	ROA	14.49%	Short Interest	8.02M	Perf YTD	0.51%
Book/sh	16.63	P/C	228.32	EPS next 5Y	41.72%	ROE	77.73%	52W High	972.53 -20.22%	Perf Year	-14.65%
Cash/sh	3.40	P/FCF	196.80	EPS past 3/5Y	24.14% 18.77%	ROIC	22.10%	52W Low	677.09 14.59%	Perf 3Y	138.28%
Dividend Est.	6.24 (0.80%)	EV/EBITDA	35.76	Sales past 3/5Y	16.73% 15.08%	Gross Margin	81.70%	Volatility	2.37% 2.35%	Perf 5Y	394.11%
Dividend TTM	5.60 (0.72%)	EV/Sales	15.73	EPS Y/Y TTM	80.73%	Oper. Margin	40.25%	ATR (14)	20.60	Perf 10Y	838.55%
Dividend Ex-Date	Aug 15, 2025	Quick Ratio	1.06	Sales Y/Y TTM	36.38%	Profit Margin	22.66%	RSI (14)	49.18	Recom	1.53
Dividend Gr. 3/5Y	15.21% 15.05%	Current Ratio	1.37	EPS Q/Q	23.46%	SMA20	-1.08%	Beta	0.40	Target Price	987.83
Payout	44.39%	Debt/Eq	2.44	Sales Q/Q	45.17%	SMA50	-0.68%	Rel Volume	0.66	Prev Close	779.53
Employees	47000	LT Debt/Eq	2.19	Earnings	May 01 BMO	SMA200	-5.23%	Avg Volume	4.12M	Price	775.90
IPO	Jul 09, 1970	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.51% 0.48%	Trades		Volume	2,732,543	Change	-0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-25	Downgrade	Erste Group	Buy → Hold
Apr-28-25	Downgrade	HSBC Securities	Buy → Reduce	$1150 → $700
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$975
Dec-10-24	Resumed	BofA Securities	Buy	$997
Nov-15-24	Initiated	Wolfe Research	Outperform	$1000
Oct-17-24	Initiated	Bernstein	Outperform	$1100
Sep-13-24	Resumed	Citigroup	Buy	$1060
Aug-12-24	Upgrade	Deutsche Bank	Hold → Buy	$1025
Feb-21-24	Downgrade	DZ Bank	Buy → Hold	$820
Feb-16-24	Reiterated	Morgan Stanley	Overweight	$805 → $950
Dec-21-23	Downgrade	Daiwa Securities	Buy → Outperform	$660 → $610
Nov-09-23	Initiated	Deutsche Bank	Hold	$535
Oct-20-23	Resumed	UBS	Buy	$612 → $710
Aug-09-23	Upgrade	Jefferies	Hold → Buy	$408 → $615
Jul-26-23	Reiterated	Citigroup	Buy	$360 → $525
Jul-14-23	Initiated	HSBC Securities	Buy	$560
May-24-23	Reiterated	UBS	Buy	$447 → $498
May-24-23	Reiterated	BofA Securities	Buy	$450 → $500
Mar-13-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$360 → $375
Mar-06-23	Initiated	Jefferies	Hold	$290

Show Previous Ratings

Today 09:00AM	Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock (Zacks)
06:20AM	Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? (Zacks)
06:20AM	Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)? (Zacks)
06:06AM	How Novo Nordisk misread the US market for its weight loss sensation (Reuters)
Jun-30-25 05:08PM	FDA Approves Updated Label For Eli Lilly and Company (LLY)'s Amyvid To Support Alzheimer's Diagnosis (Insider Monkey)
04:09PM	Loading…
04:09PM	Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? (Investor's Business Daily)
01:30PM	Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story (Barchart)
10:27AM	Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised) (Zacks)
08:18AM	RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimers market (Investing.com)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-28-25 06:47AM	Which Stock Will Dominate the Weight Management Market Through 2030? (Motley Fool)
Jun-27-25 11:10AM	NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now? (Zacks)
10:10AM	Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed? (Zacks)
10:08AM	AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock (Zacks)
09:53AM	BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside (Investing.com)
11:12AM	Loading…
Jun-26-25 11:12AM	VKTX Initiates Phase 3 Study on Obesity Candidate VK2735 (Zacks)
09:43AM	Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth? (Zacks)
07:31AM	Eli Lilly receives FDA approval for Amyvid label update (Pharmaceutical Technology)
02:59AM	5 Revealing Analyst Questions From Eli Lilly's Q1 Earnings Call (StockStory)
Jun-25-25 02:09PM	Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity (Investor's Business Daily)
12:20PM	Eli Lilly and Company (LLY) Is Going To Be A "Trillion-Dollar Market Cap," Says Jim Cramer (Insider Monkey)
11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
09:07AM	Novo Nordisk split puts Hims & Hers future in question (Yahoo Finance)
07:32AM	Citi bullish on Lilly as Orforglipron unlocks $40B+ obesity market (Investing.com)
06:05AM	3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow (Motley Fool)
05:56AM	United States Insulin Pens Market Research Report 2025-2033, Advances in Technology, Favorable Reimbursement Policies, Increasing Awareness and Adoption (GlobeNewswire)
03:47AM	Eli Lilly Mounjaro Sees Strong Reception in India, Rising Demand Amid Obesity, Diabetes Rates (Insider Monkey)
03:00AM	Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director (GlobeNewswire)
Jun-24-25 05:50PM	The Weight Loss Drug Market Has Gotten Messy. What to Know. (Barrons.com)
11:49AM	Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care (Zacks)
11:25AM	Loading…
11:25AM	Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers? (Zacks)
10:25AM	Pfizer to Face Several Headwinds: Can It Successfully Navigate Them? (Zacks)
09:45AM	New AI Rollouts Signal Shift From Hype to Healthcare Reality (PR Newswire)
09:20AM	Will CVS Health's Formulary Move Boost Its Weight Management Program? (Zacks)
04:25AM	Eli Lilly (LLY) Retains $1,100 Price Target at Bernstein Ahead of Diabetes Conference (Insider Monkey)
12:01AM	Novo Nordisk Backs Away From Hims & Hers Partnership (The Daily Upside)
Jun-23-25 05:45PM	Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
04:15PM	Amgen Shares Fall on Weight-Loss Drug Tummy Troubles (Barrons.com)
02:50PM	HIMS Stock Crashes 30% in a Day: Time to Buy the Dip? (Zacks)
02:30PM	Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment (Yahoo Finance)
12:37PM	NovoHims & Hers deal ends, Eli Lilly GLP-1 pill: What to know (Yahoo Finance Video)
12:18PM	Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices (Investopedia)
12:01PM	Eli Lilly seeks green light for weekly insulin after strong trial results (Clinical Trials Arena)
11:39AM	Hims & Hers stock plunges after Novo Nordisk ends Wegovy direct sales deal (Yahoo Finance)
11:39AM	Hims & Hers stock plummets after Novo Nordisk ends Wegovy direct sales deal (Yahoo Finance)
11:37AM	Lilly declares third-quarter 2025 dividend (PR Newswire)
11:20AM	Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints (Investopedia)
11:09AM	'Quality' Stocks Just Ain't What They Used to Be (Barrons.com)
10:05AM	Hims & Hers' stock plunges. Here's why Wegovy parent ended its partnership with the company. (MarketWatch)
09:17AM	Novo Nordisk Stock Drops on Weight-Loss Data. Why Investors Have Doubts. (Barrons.com)
06:21AM	Novo Nordisk shares fall as obesity pipeline faces investor scrutiny (Reuters)
04:00AM	Megablockbusters are the holy grail. Heres how drugmakers are getting there. (Pharma Voice)
Jun-22-25 02:31PM	Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials (PR Newswire)
Jun-21-25 09:06AM	Lilly expects orforglipron obesity results in third quarter (Reuters)
09:01AM	Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine (PR Newswire)
Jun-20-25 03:45PM	Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says (Reuters)
03:00PM	A $1.3 Billion Reason to Buy Eli Lilly Stock Now (Barchart)
01:07PM	Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week (Motley Fool)
12:49PM	How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl (Investor's Business Daily)
09:30AM	Ricks Is the King of Pharma, Thanks to Lilly's Zepbound (Barrons.com)
09:28AM	LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet? (Zacks)
09:00AM	Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:04AM	McDonald's Is Down, But Long-Term Investors Can Still Take a Bite (MarketBeat)
06:34AM	This AI Trader Bought Meta Stock and Dumped Eli Lilly (Barrons.com)
04:51AM	Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand (Reuters)
Jun-19-25 10:23AM	What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? (Zacks)
09:45AM	SanDisk initiated, Analog Devices upgraded: Wall Streets top analyst calls (TipRanks)
08:03AM	RyboDyn Selected to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome (PR Newswire)
07:55AM	Eli Lilly and Eisais Alzheimers drugs denied NHS use due to high costs (Pharmaceutical Technology)
03:55AM	5 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
Jun-18-25 11:31PM	Q1 Earnings Outperformers: Eli Lilly (NYSE:LLY) And The Rest Of The Branded Pharmaceuticals Stocks (StockStory)
02:08PM	How a Solar Factory in the Heartland Sees the 'Big Beautiful Bill' (Barrons.com)
11:40AM	Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results (Investopedia)
10:52AM	Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space? (Zacks)
10:22AM	GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold? (Zacks)
10:00AM	Trump administration weighs crackdown on pharma ads, Bloomberg says (TipRanks)
09:53AM	Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. (Motley Fool)
09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
07:45AM	Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy? (Motley Fool)
03:37AM	Adam Parker of Trivariate Research Recommends Eli Lilly's Dividend as a Defensive Play (Insider Monkey)
Jun-17-25 05:49PM	Podcast: U.S. Stocks Slip as Israel-Iran Conflict Continues (The Wall Street Journal)
04:34PM	These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More (Barrons.com)
03:59PM	Solar stocks, Eli Lilly & Verve, PureCycle: Trending Tickers (Yahoo Finance Video)
02:47PM	These Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More (Barrons.com)
01:28PM	Eli Lilly lands bargain deal to acquire Verve Therapeutics for $1.3bn (Pharmaceutical Technology)
01:27PM	Lilly to buy gene-editing partner Verve for $1.3 billion (CNBC TV)
12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com)
12:12PM	Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly (Zacks)
12:03PM	Top Stock Movers Now: Enphase Energy, T-Mobile US, Jabil, and More (Investopedia)
11:20AM	UBS Maintains Price Target on Eli Lilly (LLY) Despite CVS Shift to Wegovy (Insider Monkey)
11:18AM	AMD extends gains, solar stocks plummet, pharma stocks (Yahoo Finance Video)
11:08AM	Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion (GuruFocus.com)
11:05AM	Why Verve Therapeutics Stock Is Skyrocketing Today (Motley Fool)
10:02AM	Eli Lillys $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. (Barrons.com)
09:53AM	T-Mobile & Softbank, solar, Eli Lilly & Verve: Trending Tickers (Yahoo Finance Video)
09:33AM	Members of Congress Are Pouring Millions Into These 7 Surprising Stocks (Motley Fool)
09:15AM	Verve Therapeutics Skyrockets - Pulling Gene-Editing Stocks Higher - On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
08:14AM	Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B (Investopedia)
08:13AM	This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly (MarketWatch)
07:55AM	Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion (The Wall Street Journal)

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zakrowski Donald A	SVP, Finance, & CAO	May 27 '25	Sale	716.41	1,000	716,410	4,840	May 27 04:13 PM
Yuffa Ilya	EVP & President, LLY Int'l	May 14 '25	Sale	749.24	1,250	936,550	27,510	May 15 04:17 PM
Yuffa Ilya	Officer	May 14 '25	Proposed Sale	749.24	2,500	1,873,100		May 14 12:25 PM
DONALD ZAKROWSKI	Officer	Mar 13 '25	Proposed Sale	821.86	2,000	1,643,720		Mar 13 04:57 PM
Zakrowski Donald A	SVP, Finance, & CAO	Mar 13 '25	Sale	818.24	1,000	818,240	5,840	Mar 13 04:17 PM
LILLY ENDOWMENT INC	10% Owner	Mar 03 '25	Sale	928.76	220,000	204,326,151	96,016,978	Mar 04 04:00 PM
Dozier Eric	EVP, Chief People Officer	Mar 01 '25	Option Exercise	0.00	2,403	0	10,905	Mar 03 04:53 PM
Hernandez Edgardo	EVP & Pres., Mfg. Operations	Mar 01 '25	Option Exercise	0.00	2,837	0	41,009	Mar 03 04:51 PM
LILLY ENDOWMENT INC	10% Owner	Mar 03 '25	Proposed Sale	920.63	220,000	202,538,600		Mar 03 03:34 PM
LILLY ENDOWMENT INC	10% Owner	Feb 25 '25	Sale	903.07	225,000	203,190,794	96,236,978	Feb 26 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 24 '25	Sale	883.97	60,432	53,419,955	96,461,978	Feb 25 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 25 '25	Proposed Sale	881.40	225,000	198,315,000		Feb 25 03:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 21 '25	Sale	882.70	99,452	87,786,505	96,522,410	Feb 24 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 20 '25	Sale	877.99	14,685	12,893,353	96,621,862	Feb 21 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 19 '25	Sale	878.45	9,985	8,771,285	96,636,547	Feb 20 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 13 '25	Sale	879.52	35,446	31,175,396	96,646,532	Feb 14 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 13 '25	Proposed Sale	872.97	220,000	192,053,400		Feb 13 03:43 PM
Skovronsky Daniel	EVP, CSO & Pres. LRL & LLY Imm	Feb 10 '25	Sale	863.21	5,000	4,316,065	117,888	Feb 12 04:15 PM
Skovronsky Daniel	Officer	Feb 10 '25	Proposed Sale	863.19	5,000	4,315,954		Feb 10 11:44 AM
LILLY ENDOWMENT INC	10% Owner	Feb 06 '25	Sale	874.13	210,000	183,567,262	96,681,978	Feb 07 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 06 '25	Proposed Sale	842.18	210,000	176,857,800		Feb 06 04:04 PM
Yuffa Ilya	EVP & President, LLY Int'l	Feb 01 '25	Option Exercise	0.00	3,269	0	23,071	Feb 04 04:28 PM
White Anne E.	EVP & Pres, Lilly Neuroscience	Feb 01 '25	Option Exercise	0.00	3,269	0	68,838	Feb 04 04:27 PM
Van Naarden Jacob	EVP & Pres., Lilly Oncology	Feb 01 '25	Option Exercise	0.00	3,023	0	14,868	Feb 04 04:26 PM
Skovronsky Daniel	EVP, CSO & Pres. LRL & LLY Imm	Feb 01 '25	Option Exercise	0.00	8,989	0	126,892	Feb 04 04:25 PM
Ricks David A	President, Chair, and CEO	Feb 01 '25	Option Exercise	0.00	26,561	0	496,385	Feb 04 04:24 PM
Rau Diogo	EVP & CIDO	Feb 01 '25	Option Exercise	0.00	3,269	0	14,370	Feb 04 04:23 PM
Jonsson Patrik	EVP&Pres, CardMetHlth, LLY USA	Feb 01 '25	Option Exercise	0.00	3,433	0	48,016	Feb 04 04:23 PM
Hernandez Edgardo	EVP & Pres., Mfg. Operations	Feb 01 '25	Option Exercise	0.00	2,861	0	33,479	Feb 04 04:21 PM
Hakim Anat	EVP, GC & Secretary	Feb 01 '25	Option Exercise	0.00	4,904	0	20,683	Feb 04 04:19 PM
Zakrowski Donald A	Officer	Nov 08 '24	Proposed Sale	803.38	900	723,042		Nov 08 04:54 PM
Zakrowski Donald A	SVP, Finance, & CAO	Nov 08 '24	Sale	803.38	900	723,042	5,480	Nov 08 04:18 PM
Montarce Lucas	EVP & CFO	Nov 01 '24	Option Exercise	0.00	1,074	0	11,541	Nov 05 04:15 PM
Hernandez Edgardo	EVP & Pres., Mfg. Operations	Nov 01 '24	Option Exercise	0.00	1,687	0	31,369	Nov 05 04:14 PM
Dozier Eric	EVP, HR & Diversity	Nov 01 '24	Option Exercise	0.00	1,534	0	8,724	Nov 05 04:13 PM
LILLY ENDOWMENT INC	10% Owner	Sep 03 '24	Sale	966.69	24,084	23,281,840	96,891,978	Sep 04 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Aug 27 '24	Sale	968.46	24,552	23,777,668	96,916,062	Aug 28 04:05 PM
Zakrowski Donald A	Officer	Aug 26 '24	Proposed Sale	950.00	750	712,500		Aug 26 04:47 PM
Zakrowski Donald A	SVP, Finance, & CAO	Aug 26 '24	Sale	950.00	750	712,500	6,380	Aug 26 04:21 PM
LILLY ENDOWMENT INC	10% Owner	Aug 22 '24	Sale	966.33	3,196	3,088,382	96,940,614	Aug 23 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Aug 22 '24	Proposed Sale	951.97	215,000	204,673,550		Aug 22 12:54 PM
LILLY ENDOWMENT INC	10% Owner	Jul 10 '24	Sale	939.82	210,000	197,361,398	96,943,810	Jul 11 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jul 08 '24	Sale	918.64	93,593	85,977,954	97,153,810	Jul 09 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jul 05 '24	Sale	915.18	52,369	47,927,194	97,247,403	Jul 08 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jul 03 '24	Sale	915.31	8,848	8,098,655	97,299,772	Jul 03 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LLY

Lilly(Eli) & Co

Upgrade your FINVIZ experience